Business
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
CHICAGO--(BUSINESS WIRE)-- Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions. The updated
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nPlease replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.\n\n\nThe updated release reads:\n\n\nCARDIO DIAGNOSTICS HOLDINGS, INC. TO HOST INVESTOR CALL ON THURSDAY, FEBRUARY 19, 2026\n\n\nCardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, February 19, 2026, at 3 p.m. Central Time.\n\n\nThe call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives.\n\n\nWebcast and Conference Call Details\n\n\nDate: Thursday, February 19, 2026\nTime: 3 p.m. Central Time\nWebcast: https://www.cstproxy.com/cardiodiagnosticsinc/investorday/2026\n\n\nTo access the conference call by telephone, U.S. and Canada-based callers should dial 1 800-450-7155 (toll-free), and callers from outside the U.S. and Canada should dial +1 857-999-9155 (standard rates apply). Participants should use the passcode provided below to join.\n\n\nPasscode: 3253181#\n\n\nA replay of the webcast will be available via the webcast link above following the conclusion of the call.\n\n\nAbout Cardio Diagnostics\n\n\nCardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (\"Core Technology\") for cardiovascular disease. For more information, please visit https://cdio.ai/.\n\n\nForward-Looking Statements\n\n\nCertain statements and information included in this press release constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases \"will,\" ...